Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 5293 to 5297 of 5297 entries
Sorted by: Best Match Show Resources per page
A prospective multicenter study of the magnifying endoscopic evaluation of the invasion depth of superficial esophageal cancers.

Surgical endoscopy

Gotoda T, Hori K, Nakagawa M, Kobayashi S, Toyokawa T, Ishiyama S, Imagawa A, Abe M, Kono Y, Kanzaki H, Iwamuro M, Kawano S, Kawahara Y, Okada H.
PMID: 34322721
Surg Endosc. 2021 Jul 28; doi: 10.1007/s00464-021-08666-w. Epub 2021 Jul 28.

BACKGROUND: Treatment strategies for superficial esophageal squamous cell carcinoma (SESCC) are determined mainly on the basis of the invasion depth. The Japan Esophageal Society (JES) developed a simplified magnifying endoscopic classification for estimating the invasion depth of SESCC. We...

Cite
Gotoda T, Hori K, Nakagawa M, et al. A prospective multicenter study of the magnifying endoscopic evaluation of the invasion depth of superficial esophageal cancers. Surg Endosc. 2021;doi: 10.1007/s00464-021-08666-w.
Gotoda, T., Hori, K., Nakagawa, M., Kobayashi, S., Toyokawa, T., Ishiyama, S., Imagawa, A., Abe, M., Kono, Y., Kanzaki, H., Iwamuro, M., Kawano, S., Kawahara, Y., & Okada, H. (2021). A prospective multicenter study of the magnifying endoscopic evaluation of the invasion depth of superficial esophageal cancers. Surgical endoscopy, . https://doi.org/10.1007/s00464-021-08666-w
Gotoda, Tatsuhiro, et al. "A prospective multicenter study of the magnifying endoscopic evaluation of the invasion depth of superficial esophageal cancers." Surgical endoscopy vol. (2021). doi: https://doi.org/10.1007/s00464-021-08666-w
Gotoda T, Hori K, Nakagawa M, Kobayashi S, Toyokawa T, Ishiyama S, Imagawa A, Abe M, Kono Y, Kanzaki H, Iwamuro M, Kawano S, Kawahara Y, Okada H. A prospective multicenter study of the magnifying endoscopic evaluation of the invasion depth of superficial esophageal cancers. Surg Endosc. 2021 Jul 28; doi: 10.1007/s00464-021-08666-w. Epub 2021 Jul 28. PMID: 34322721.
Copy Download .nbib Format: NLM
Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas.

Cancers

Shoji T, Tatsuki S, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Baba T, Itamochi H.
PMID: 34885229
Cancers (Basel). 2021 Dec 04;13(23). doi: 10.3390/cancers13236120.

Ovarian cancer has the worst prognosis among gynecological cancers. In particular, clear cell and mucinous carcinomas are less sensitive to chemotherapy. The establishment of new therapies is necessary to improve the treatment outcomes for these carcinomas. In previous clinical...

Cite
Shoji T, Tatsuki S, Abe M, et al. Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. Cancers (Basel). 2021;13(23)doi: 10.3390/cancers13236120.
Shoji, T., Tatsuki, S., Abe, M., Tomabechi, H., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M., Baba, T., & Itamochi, H. (2021). Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. Cancers, 13(23), . https://doi.org/10.3390/cancers13236120
Shoji, Tadahiro, et al. "Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas." Cancers vol. 13,23 (2021). doi: https://doi.org/10.3390/cancers13236120
Shoji T, Tatsuki S, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Baba T, Itamochi H. Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. Cancers (Basel). 2021 Dec 04;13(23). doi: 10.3390/cancers13236120. PMID: 34885229; PMCID: PMC8656608.
Copy Download .nbib Format: NLM
Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.

Annals of hematology

Sato K, Okazuka K, Ishida T, Sakamoto J, Kaneko S, Nashimoto J, Uto Y, Ogura M, Yoshiki Y, Abe Y, Maeda A, Hamazaki H, Tsukada N, Hiragohri Y, Suzuki K.
PMID: 34430990
Ann Hematol. 2021 Dec;100(12):2989-2995. doi: 10.1007/s00277-021-04634-5. Epub 2021 Aug 25.

Minimal residual disease (MRD)-negative status in multiple myeloma (MM) is associated with favorable outcomes. Although EuroFlow next-generation flow (NGF) is a global standard for MRD detection, its operating cost is high. Therefore, it is desirable to develop a less...

Cite
Sato K, Okazuka K, Ishida T, et al. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry. Ann Hematol. 2021;100(12):2989-2995doi: 10.1007/s00277-021-04634-5.
Sato, K., Okazuka, K., Ishida, T., Sakamoto, J., Kaneko, S., Nashimoto, J., Uto, Y., Ogura, M., Yoshiki, Y., Abe, Y., Maeda, A., Hamazaki, H., Tsukada, N., Hiragohri, Y., & Suzuki, K. (2021). Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry. Annals of hematology, 100(12), 2989-2995. https://doi.org/10.1007/s00277-021-04634-5
Sato, Kota, et al. "Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry." Annals of hematology vol. 100,12 (2021): 2989-2995. doi: https://doi.org/10.1007/s00277-021-04634-5
Sato K, Okazuka K, Ishida T, Sakamoto J, Kaneko S, Nashimoto J, Uto Y, Ogura M, Yoshiki Y, Abe Y, Maeda A, Hamazaki H, Tsukada N, Hiragohri Y, Suzuki K. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry. Ann Hematol. 2021 Dec;100(12):2989-2995. doi: 10.1007/s00277-021-04634-5. Epub 2021 Aug 25. PMID: 34430990.
Copy Download .nbib Format: NLM
Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Kohi S, Macgregor-Das A, Dbouk M, Yoshida T, Chuidian M, Abe T, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M.
PMID: 33161160
Clin Gastroenterol Hepatol. 2022 Feb;20(2):e196-e227. doi: 10.1016/j.cgh.2020.11.006. Epub 2020 Nov 05.

BACKGROUND & AIMS: The tumor microbiome of patients with pancreas ductal adenocarcinoma (PDAC) includes bacteria normally present in the upper gastrointestinal tract. If the predominant source of intratumoral bacteria in patients with PDAC is retrograde migration from the duodenum,...

Cite
Kohi S, Macgregor-Das A, Dbouk M, et al. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2020;20(2):e196-e227doi: 10.1016/j.cgh.2020.11.006.
Kohi, S., Macgregor-Das, A., Dbouk, M., Yoshida, T., Chuidian, M., Abe, T., Borges, M., Lennon, A. M., Shin, E. J., Canto, M. I., & Goggins, M. (2022). Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 20(2), e196-e227. https://doi.org/10.1016/j.cgh.2020.11.006
Kohi, Shiro, et al. "Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 20,2 (2022): e196-e227. doi: https://doi.org/10.1016/j.cgh.2020.11.006
Kohi S, Macgregor-Das A, Dbouk M, Yoshida T, Chuidian M, Abe T, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2022 Feb;20(2):e196-e227. doi: 10.1016/j.cgh.2020.11.006. Epub 2020 Nov 05. PMID: 33161160; PMCID: PMC8120597.
Copy Download .nbib Format: NLM
Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis.

JCI insight

Marek-Iannucci S, Ozdemir AB, Moreira D, Gomez AC, Lane M, Porritt RA, Lee Y, Shimada K, Abe M, Stotland A, Zemmour D, Parker S, Sanchez-Lopez E, Van Eyk J, Gottlieb RA, Fishbein MC, Karin M, Crother TR, Rivas MN, Arditi M.
PMID: 34403365
JCI Insight. 2021 Sep 22;6(18). doi: 10.1172/jci.insight.151981.

Kawasaki disease (KD) is the leading cause of acquired heart disease among children. Murine and human data suggest that the NLRP3-IL-1β pathway is the main driver of KD pathophysiology. NLRP3 can be activated during defective autophagy/mitophagy. We used the...

Cite
Marek-Iannucci S, Ozdemir AB, Moreira D, et al. Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis. JCI Insight. 2021;6(18)doi: 10.1172/jci.insight.151981.
Marek-Iannucci, S., Ozdemir, A. B., Moreira, D., Gomez, A. C., Lane, M., Porritt, R. A., Lee, Y., Shimada, K., Abe, M., Stotland, A., Zemmour, D., Parker, S., Sanchez-Lopez, E., Van Eyk, J., Gottlieb, R. A., Fishbein, M. C., Karin, M., Crother, T. R., Rivas, M. N., & Arditi, M. (2021). Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis. JCI insight, 6(18), . https://doi.org/10.1172/jci.insight.151981
Marek-Iannucci, Stefanie, et al. "Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis." JCI insight vol. 6,18 (2021). doi: https://doi.org/10.1172/jci.insight.151981
Marek-Iannucci S, Ozdemir AB, Moreira D, Gomez AC, Lane M, Porritt RA, Lee Y, Shimada K, Abe M, Stotland A, Zemmour D, Parker S, Sanchez-Lopez E, Van Eyk J, Gottlieb RA, Fishbein MC, Karin M, Crother TR, Rivas MN, Arditi M. Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis. JCI Insight. 2021 Sep 22;6(18). doi: 10.1172/jci.insight.151981. PMID: 34403365; PMCID: PMC8492304.
Copy Download .nbib Format: NLM
Showing 5293 to 5297 of 5297 entries